Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lucatumumab + bendamustine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination of **lucatumumab**, a fully human monoclonal antibody targeting CD40, and **bendamustine**, a bifunctional alkylating agent. Lucatumumab acts by blocking the interaction of CD40L with CD40 on B cells, thereby inhibiting cell proliferation and survival signals. It also induces antibody-dependent cell-mediated cytotoxicity (ADCC). Bendamustine crosslinks DNA, disrupting DNA/RNA synthesis and repair, leading to cell death via both apoptotic and nonapoptotic mechanisms. This combination is being investigated primarily for the treatment of **chronic lymphocytic leukemia (CLL)** and potentially other B-cell malignancies[5][2][4][6].
- Other names
- lucatumumabbendamustine
02
Targets
DNACD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on lucatumumab + bendamustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lucatumumab + bendamustine.